FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Tolvaptan could be the first oral vasopressin receptor antagonist on the market.
You may also be interested in...
FDA Panel Blesses Otsuka’s Hyponatremia Drug
Oral therapy jumps efficacy-but-no-clinical-benefit hurdle.
FDA Panel Blesses Otsuka’s Hyponatremia Drug
Oral therapy jumps efficacy-but-no-clinical-benefit hurdle.
Defining Efficacy Without Proof Of Benefit: FDA Panel To Assess Otsuka’s Samska
Cardio-Renal Advisory Committee meets June 25 to review tolvaptan’s effect on serum sodium in hyponatremia.